215
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Case Report: Severe Toxicity in an African–American Patient Receiving FOLFOX Carrying Uncommon Allelic Variants in DPYD

ORCID Icon, ORCID Icon, ORCID Icon, , ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 81-85 | Received 25 Aug 2020, Accepted 26 Oct 2020, Published online: 11 Dec 2020

References

  • Wagner AD , SynNL , MoehlerMet al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev.8, CD004064 (2017).
  • Lunenburg C , HenricksLM , GuchelaarHJet al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time. Eur. J. Cancer54, 40–48 (2016).
  • Amstutz U , HenricksLM , OfferSMet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin. Pharmacol. Ther.103(2), 210–216 (2018).
  • Burmester JK , SedovaM , ShaperoMH , MansfieldE. DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol. Biol.632, 99–124 (2010).
  • Campbell JM , BatemanE , PetersM , BowenJM , KeefeDM , StephensonMD. Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics17(4), 435–451 (2016).
  • Lam SW , GuchelaarHJ , BovenE. The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat. Rev.50, 9–22 (2016).
  • National Center for Biotechnology Information (US) . DeanL. Fluorouracil therapy and DPYD genotype. In: Medical Genetics SummariesPrattVM, McLeodHL, RubinsteinWS ( Eds). National Center for Biotechnology Information, MD, USA (2012).
  • Varma KA , JayanthiM , DubashiB , ShewadeDG. Influence of DPYD*9A, DPYD*6 and GSTP1 ile105val genetic polymorphisms on capecitabine and oxaliplatin (CAPOX) associated toxicities in colorectal cancer (CRC) patients. Asian Pac. J. Cancer Prev.20(10), 3093–3100 (2019).
  • Peng Z , WangQ , GaoJet al. Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis. Cancer Chemother. Pharmacol.72(2), 305–314 (2013).
  • Rosmarin D , PallesC , PagnamentaAet al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut64(1), 111–120 (2015).
  • Kosovec JE , EgorinMJ , GjurichS , BeumerJH. Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom.22(2), 224–230 (2008).
  • Morawska K , GoirandF , MarceauLet al. 5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer. Oncotarget9(14), 11559–11571 (2018).
  • Genomes Project C , AutonA , BrooksLDet al. A global reference for human genetic variation. Nature526(7571), 68–74 (2015).
  • Offer SM , LeeAM , MattisonLK , FossumC , WegnerNJ , DiasioRB. A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity. Clin. Pharmacol. Ther.94(1), 158–166 (2013).
  • Saif MW , LeeAM , OfferSM , McconnellK , ReliasV , DiasioRB. A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. Mayo Clin. Proc.89(1), 131–136 (2014).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.